Scilex Holding (SCLX) Net Cash Flow (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Net Cash Flow of $1.1 million for Q1 2026, down 57.12% year-over-year from $2.5 million in Q1 2025, and down 77.57% on a QoQ basis from $4.8 million in Q4 2025.
Scilex Holding (SCLX) Net Cash Flow (2020 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Net Cash Flow for 7 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 57.12% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $995000.0 (down 67.12% YoY), while the FY2025 annual figure was $2.4 million, up 267.4% from the prior year.
- Net Cash Flow came in at $1.1 million for Q1 2026 at Scilex Holding, down from $4.8 million in the prior quarter.
- The five-year high for Net Cash Flow was $30.1 million in Q2 2023, with the low at -$33.1 million in Q3 2023.
- Average Net Cash Flow over 5 years is $144529.4, with a median of -$299000.0 recorded in 2022.
- The largest YoY upside for Net Cash Flow was 9813.22% in 2022 against a maximum downside of 11419.18% in 2022.
- Year by year, Net Cash Flow stood at -$299000.0 in 2022, then surged by 1019.4% to $2.7 million in 2023, then tumbled by 276.21% to -$4.8 million in 2024, then jumped by 199.77% to $4.8 million in 2025, then tumbled by 77.57% to $1.1 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $1.1 million, $4.8 million, and -$3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -2.05 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 2.00 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 4.17 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -1.53 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -9.27 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 2.91 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 75.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 544.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 1.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.08 Mn |
| Mar 31, 2026 | 1.08 Mn |
| Dec 31, 2025 | 4.83 Mn |
| Dec 31, 2025 | 4.83 Mn |
| Sep 30, 2025 | -3.26 Mn |
| Sep 30, 2025 | -3.26 Mn |
| Jun 30, 2025 | -1.66 Mn |
| Jun 30, 2025 | -1.66 Mn |
| Mar 31, 2025 | 2.53 Mn |
| Mar 31, 2025 | 2.53 Mn |
| Dec 31, 2024 | -4.84 Mn |
| Dec 31, 2024 | -4.84 Mn |
| Sep 30, 2024 | -1.55 Mn |
| Sep 30, 2024 | -1.55 Mn |
| Jun 30, 2024 | 6.89 Mn |
| Jun 30, 2024 | 6.89 Mn |
| Mar 31, 2024 | -1.96 Mn |
| Mar 31, 2024 | -1.96 Mn |
| Dec 31, 2023 | 2.75 Mn |
| Dec 31, 2023 | 2.75 Mn |